Sunday, March 15, 2009

Faster Diagnosis Benefits Acute Chest Pain Patients

Accelerated diagnostic protocol linked to psychological benefits and improved quality of life

15 mar 2009-- In low-risk patients who present to hospitals with acute chest pain, an accelerated diagnostic protocol may be associated with less impairment of quality of life than usual care, according to a report published in the Mar. 1 issue of the American Journal of Cardiology.

Gaetano Nucifora, M.D., of the University Hospital S. Maria della Misericordia in Udine, Italy, and colleagues studied 290 patients who had a non-diagnostic electrocardiogram and negative biomarkers. The subjects were randomly assigned to either one of two accelerated diagnostic protocols -- dobutamine-atropine stress echocardiography (DASE) or electrocardiogram exercise testing (EET) -- or usual care, and their quality of life was assessed with the Nottingham Health Profile questionnaire.

Compared to the DASE and EET groups, the usual care group reported more impaired mobility and pain before discharge from the hospital, the investigators found. The usual care group also had significantly worse scores for physical mobility, pain, social isolation, emotional reactions and energy levels at the two-month follow-up, the researchers report.

"Our study also showed that low-risk patients with acute chest pain experienced psychological benefits using an accelerated diagnostic workup with early DASE or EET that allowed an immediate discharge in case of negative stress test results compared with usual care," the authors write. "The benefit provided by the accelerated diagnostic protocols was already visible at pre-discharge and was maintained during follow-up, although significant improvement in quality of life was observed in all three groups after two months."

Abstract
Full Text (subscription or payment may be required)

Folic Acid Supplements Linked to Prostate Cancer Risk

In separate study, definition of 'lead time' can affect outcome in prostate cancer screening research

15 mar 2009-- Folic acid supplementation may be associated with a higher risk of prostate cancer, and different definitions of "lead time" in studies on screening with prostate-specific antigen (PSA) can affect their outcome, according to two reports published online Mar. 10 in the Journal of the National Cancer Institute.

In the first study, Jane C. Figueiredo, Ph.D., of the University of Southern California in Los Angeles, and colleagues analyzed data from 643 men in a polyp prevention study who were randomized to receive placebo or folic acid supplementation. The estimated probability of being diagnosed with prostate cancer over 10 years was 9.7 percent in the treatment group and 3.3 percent in the placebo group, for an age-adjusted hazard ratio of 2.63 percent.

In the other study, Gerrit Draisma, Ph.D., of the University Medical Center in Rotterdam, the Netherlands, and colleagues used three models of prostate cancer progression and detection that were calibrated to Surveillance, Epidemiology, and End Results incidence data to estimate lead times and overdiagnosis associated with PSA screening. Estimated mean lead times varied from 5.4 to 6.9 years, and overdiagnosis ranged from 23 to 42 percent of all cancers found by PSA testing, the researchers report.

"Using the folate supplementation trial as an example, it is not unreasonable to assume that optimal levels of folate are associated with more fidelity in DNA replication and thus a lower risk of spontaneous mutations, but high folate may also support more rapid cell growth and promote carcinogenesis in previously initiated cells. It is safe to conclude that cancer prevention is not going to be as simple as recommending high-dose micronutrient supplements for middle-aged and older adults," write the authors of an editorial accompanying the Figueiredo study.

In the Figueiredo study, Wyeth provided study agents for the underlying clinical trial, and one of the study co-authors is a consultant for Prozen, Inc.

Abstract - Figueiredo
Full Text (subscription or payment may be required)
Editorial
Abstract- Draisma
Full Text (subscription or payment may be required)
Editorial

Statins May Drain Energy Along with Cholesterol

Compared to placebo, simvastatin and pravastatin associated with decreased levels of energy


15 mar 2009-- Statins effectively reduce low-density lipoprotein (LDL) cholesterol, but they also appear to reduce patients' levels of energy and activity, according to research presented at the American Heart Association's 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, held Mar. 10 to 14 in Palm Harbor, Fla.

Beatrice Golomb, M.D., of the University of California San Diego, and colleagues randomly assigned 1,016 adults who were free of diabetes or heart disease but had LDL levels between 115-190mg/dL to receive either simvastatin, pravastatin or placebo for six months. They assessed energy and activity at baseline on scales of 0-10 and again on follow-up, with a score of -2 indicating "much worse" and a score of +2 indicating "much better."

The researchers found that simvastatin was associated with a greater mean LDL reduction than pravastatin (49 mg/dL versus 40 mg/dL). Compared to placebo, however, they found that pravastatin was associated with a significantly higher proportion of patients who rated both their energy and activity levels as "much worse" and that simvastatin was associated with a significantly higher proportion of patients who rated their energy level as "much worse."

"Future studies should extend evaluation to higher statin doses; and include assessment of measured activity," the authors conclude.

Developments in age-related macular degeneration : Diagnosis and treatment

Steven R. Kaufman

15 mar 2009--Age-related macular degeneration (ARMD) is the leading cause of legal blindness of Americans over age 65 years. Severe loss of vision is usually due to exudative ARMD, of which there are about 200,000 new cases in the United States annually. Until recently, only a small fraction of patients benefited from treatment, but advances in the early diagnosis of the disease and major developments in therapy have substantially improved the prognosis of patients with ARMD. Because visual loss substantially reduces quality of life, effective management of ARMD will have increasing public health importance as the population ages. The American Academy of Ophthalmology recommends that people over age 65 years should have a comprehensive eye examination every 1 to 2 years to check for cataracts, macular degeneration, glaucoma, and other conditions. Those who complain of difficulty reading, driving at night, or adapting from sunlight to indoor lighting might have macular degeneration.

Kaufman SR. Developments in age-related macular degeneration: Diagnosis and treatment. Geriatrics. 2009;64(3):16-19.


Saturday, March 14, 2009

Studies Investigate Health Care at End of Life

Feelings of abandonment, influence of communication and race on costs, among findings

14 mar 2009-- End-of-life health care may be associated with feelings of abandonment, and its associated costs are lower after physician-patient communication but higher among minorities, according to a series of studies published in the Mar. 9 issue of the Archives of Internal Medicine.

Anthony L. Back, M.D., of the Fred Hutchinson Cancer Research Center in Seattle, and colleagues interviewed 55 terminally ill patients, along with their physicians and caregivers. Two themes were identified through these interviews: a loss of continuity between the patient and physician contributed to concerns of abandonment prior to death, and a lack of closure resulting in feelings of abandonment among patients and families at the time of death or after. Linda Ganzini, M.D., of the Portland Veterans' Affairs Medical Center in Portland, Ore., and colleagues found that worries of future physical discomfort and loss of self-sufficiency are important motivations for considering physician aid in dying among 56 Oregonians surveyed.

Baohui Zhang, of Harvard Medical School in Boston, and colleagues report that patients with advanced terminal cancer who had an end-of-life conversation with their physician had significantly lower health care costs during their final week of life compared with those that did not ($1,876 versus $2,917, respectively). Higher costs in that final week were significantly associated with a worse quality of death. Amresh Hanchate, Ph.D., of the Boston University School of Medicine, and colleagues found that end-of-life costs were 32 percent and 57 percent higher for blacks and Hispanics, respectively.

"At life's end, black and Hispanic decedents have substantially higher costs than whites. More than half of these cost differences are related to geographic, sociodemographic and morbidity differences," Hanchate and colleagues write.

An author of the final study reports a relationship with DxCG Inc., whose company's software was used to measure morbidity burden.

Abstract - Back
Full Text (subscription or payment may be required)
Abstract - Ganzini
Full Text (subscription or payment may be required)
Abstract - Zhang
Full Text (subscription or payment may be required)
Abstract - Hanchate
Full Text (subscription or payment may be required)

Epilepsy in the elderly

14 mar 2009--It is more difficult to recognize and treat epilepsy in old than in young patients. In the new edition of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2009; 106[9]: 135󈞖), Konrad J. Werhahn of the Epilepsy Center of Johannes Gutenberg University in Mainz, Germany, presents the clinical characteristics of the disease and the therapeutic options.

It is often not possible to recognize epileptic seizures unambiguously in older patients; they may be identified as confusion of unclear etiology, memory disturbance, or giddiness. Aura is a typical symptom in young patients, but is rare in old patients. Moreover, confusion after a seizure may last much longer in older patients with epilepsy, giving the impression of dementia or stroke.

Drug treatment of old patients with epilepsy is complicated. There has not yet been enough research on changes in drug distribution and decreased elimination through the liver and kidneys in epilepsy in the elderly. For this reason, many therapeutic decisions are based on experience with young epileptics, together with the knowledge of the general principles of pharmacotherapy in age. As old patients often require different drugs for a variety of diseases, drug interactions may occur. Moreover, older patients react more sensitively to drug side effects. The author discusses conventional antiepileptics, together with their side effects and interactions. Nevertheless, many questions cannot be answered with the current state of knowledge and the available studies.

###

http://www.aerzteblatt.de/v4/archiv/pdf.asp?id=63614

Journal of American College of Surgeons finds lung transplantation should be used in older patients

Study supports use in appropriate candidates under the age of 70

CHICAGO, 14 mar 2009 – New research published in the March issue of the Journal of the American College of Surgeons suggests that lung transplantation should be used with caution in patients older than 60 years and that the procedure is associated with high rates of mortality after one year in patients 70 and older.

Lung transplantation has been the gold-standard treatment for a variety of end-stage lung diseases, but candidate selection varies greatly among transplantation centers. The International Society for Heart and Lung Transplantation (ISHLT) reports that since 1985 the percentage of older patients receiving lung transplantation has increased steadily, with 24 percent of recipients in 2006 being older than age 60. This trend has raised concerns among transplant centers, since there is no consensus on potential age limits for the operation.

"These data underscore the importance of carefully considering age among potential lung transplantation recipients," said Eric S. Weiss, MD, division of cardiac surgery, The John Hopkins Hospital, Baltimore, MD. "Although age is only one of many important criteria, advanced age appears to have a major impact on post-surgical mortality. Our findings suggest that lung transplantation remains a viable option for appropriate candidates younger than age 70."

This new research study in JACS expands on previous findings reported by Dr. Weiss and colleagues. In October 2007 (93rd annual Clinical Congress Congress of the American College of Surgeons), Dr. Weiss reported that lung transplants improved survival rates in patients over 60 years of age. In this previous study the Johns Hopkins researchers looked at factors that create positive results in a 60-plus patient population, which has typically been regarded as not being the best candidates for lung transplantation. Upon analyzing patient outcomes, the researchers found that the survival rates between older and young patients were not all that different, especially at the 30-day survival period, and they concluded that this elderly patient population should not be categorically excluded from being offered the procedure as a treatment option. In the study just released in JACS, the researchers are able to make more specific recommendations for patients in the 60 to 70-years of age range, and beyond.

This new retrospective study examined 8,363 adult patients who underwent lung transplantation between 1999 and 2006. The United Network for Organ Sharing (UNOS) database provided the data, which was stratified into four quartiles (Q) of age: Q1, 18 to 45 years; Q2, 46 to 55 years; Q3, 56 to 60 years; Q4, 61 to 79 years. Patients in Q4 were further examined in smaller increments of age to assess differences in outcomes among the oldest groups of transplant recipients.

Patients in all four age quartiles had similar 30-day and 90-day mortality rates, but patients in Q4 experienced the highest mortality rates at 1-year post-transplant (21.4 percent, p=0.002). Of the 57 patients identified as 70 or older, 34 percent of the patients died during the study period. Additionally, both the 90-day and the 1-year mortality rates of the 70 years or older cohort was significantly higher than those patients under 70 (27 percent versus 9 percent for 90 day; and 42 percent versus 18 percent for 1 year; p<>

###

About the American College of Surgeons

The American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and to improve the care of the surgical patient. The College is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The College has more than 74,000 members and is the largest organization of surgeons in the world. For more information, visit www.facs.org.

Anesthesia is found to induce hyperphosphorylation of tau at sites related to Alzheimer's disease

Staten Island, NY, 14 mar 2009 – Scientists from The New York State Office of Mental Retardation and Developmental Disabilities' (OMRDD) New York State Institute for Basic Research in Developmental Disabilities (IBR) report today in the March 2009 issue of the Journal of Alzheimer's Disease that anesthesia induces phosphorylation of tau. Tau is a key neuronal protein involved in neurodegeneration in Alzheimer's disease (AD) and several other neurodegenerative disorders. Anesthesia has previously been found to be associated with cognitive impairment and the risk for AD. This study helps elucidate the molecular mechanisms underlying these associations.

The researchers found that in test animals, anesthesia for short periods (30 seconds to 5 minutes) induced tau phosphorylation at some selective phosphorylation sites to a small but significant extent. Anesthesia for a longer time (1 hour) induced much more dramatic phosphorylation at the same sites, possibly as a result of anesthesia-induced hypothermia. The observation that anesthesia did not induce global hyperphosphorylation of brain proteins, but instead specific hyperphosphorylation of tau protein at the AD-related abnormal hyperphosphorylation sites suggests that tau hyperphosphorylation might be the mechanism that links anesthesia and the risk of cognitive impairment and/or AD.

AD is the most common cause of dementia in adults and affects approximately 27 million individuals worldwide and over four million in the United States alone. Most AD cases are sporadic and are believed to be caused by multiple factors. Understanding the mechanism by which anesthesia may increase the risk for cognitive impairment will help in the design of strategies for preventing and treating dementia and AD. "This is a very important finding related to Alzheimer's disease," said OMRDD Commissioner Diana Jones Ritter. "I am pleased that these findings will lead to helping people live richer lives through the research findings."

These findings were published in the Journal of Alzheimer's Disease 2009; 16:3 (Run X, Liang Z, Zhang L, Iqbal K, Grundke-Iqbal I, Gong C-X: Anesthesia induces phosphorylation of tau. JAD 16:3; 619-626).

The study was carried out by the Brain Metabolism Laboratory at IBR. Headed by Dr. Cheng-Xin Gong, the laboratory is focusing its research on the roles of several signaling and metabolic factors in neurodegeneration and deregulated neurodevelopment, especially related to AD and autism.

Older air traffic controllers perform as well as young on job-related tasks

In a study that challenges the mandatory retirement of air traffic controllers at the age of 56 in the U.S., researchers have found that air traffic controllers up to age 64 perform as well as their young colleagues on complex, job-related tasks.

14 mar 2009--The study of Canadian air traffic controllers, who can work up to age 65, appears this month in the Journal of Experimental Psychology.

The researchers found that while older air traffic controllers experience normal age-related declines in some cognitive skills, their expertise on the job enables them to overcome these deficits and function on a par with their younger peers.

The issue of mandatory retirement is especially pressing because a large proportion of the nation's air traffic controllers are now retiring, or nearing retirement age.

According to a congressional subcommittee hearing on the matter in 2008, most of the FAA's current 14,800 controllers were hired during the mid-1980s, after then-President Ronald Reagan fired more than 11,000 controllers who had gone on strike. Several government reports have warned that the upcoming wave of retirements could undermine the safety of the nation's aviation system.

"The question we were interested in was whether older controllers could continue to do the job," said University of Illinois psychology professor Art Kramer, who conducted the study with graduate student Ashley Nunes.

"If so, perhaps we could keep these people on the job for a little longer and this way provide more time for the transition and appropriate training of new controllers."

Kramer has spent decades studying age-related declines in cognitive abilities and the factors that sometimes slow or offset the deficits that normally occur.

The new study compared older and younger controllers with one another and with their age-matched peers who were not air traffic controllers. All of the study subjects performed a battery of cognitive tasks and simulated air traffic control tasks, which varied in difficulty.

On simple cognitive tasks, the older controllers (aged 53 to 64) were similar to the older non-controllers. Compared with their younger peers (aged 20 to 27), the older subjects were slower on simple memory or decision-making tasks that were not directly related to air traffic control. But on the tests that simulated the tasks of an air traffic controller, the older and younger controllers were equally capable. (The older non-controllers had significant deficits, however.)

"Despite the fact that these old controllers are not superpeople in a cognitive sense, they still do really well on complex simulated air traffic control tasks that are representative of what they do every day," Kramer said. "They do well, one would surmise, because they've gained decades of knowledge in their profession that's allowed them to offset the costs of not having quite the memory they used to have, and certainly not being able to respond as quickly as they once could."

The study points to the distinction between "fluid intelligence" and "crystallized intelligence," Kramer said. Fluid intelligence includes memory capacity and speed of recall; crystallized intelligence is the expertise that comes from years of attention and practice.

"Fluid intelligence declines with age, as it did in our controllers," Kramer said. "But despite that, the many years of experience, the many years of building domain-relevant knowledge in their area of expertise allows them to offset or compensate for these losses in fluid intelligence and do the job really well, just as well as the younger ones."

###

Editor's note: To reach Art Kramer, call: 217-333-9532; e-mail: a-kramer@illinois.edu.

Friday, March 13, 2009

Who should take aspirin
as CVD primary preventive?

What factors should be considered for women in decision making about aspirin

JoAnn E. Manson, MD, DrPH

Which women should take aspirin for the primary prevention of cardiovascular disease? What factors should be considered in decision making about aspirin?

13 mar 2009--Only recently have clinicians had rigorous evidence to guide decision making about the use of aspirin in the primary prevention of cardiovascular disease (CVD) in women. Although it is well established that aspirin is effective in the secondary prevention of CVD and in the treatment of acute myocardial infarction (MI) among both women and men,1 there had been sparse data about the benefits and risks of aspirin in primary prevention among women until results from a large-scale trial, the Women's Health Study (WHS), were reported in 2005.2 Previously, guidelines had been largely extrapolated from results of clinical trials in men, which had suggested that aspirin reduces the incidence of first MI by 30% to 35% while having little effect on stroke.3,4

Primary prevention results in women, including results stratified by age. The WHS, the only large primary prevention trial of aspirin in women, suggested a different pattern of cardiovascular outcomes with aspirin in women compared to men. The WHS evaluated the benefits and risks of low-dose aspirin (100 mg on alternate days) in the primary prevention of major cardiovascular events (MI, stroke, and cardiovascular death) among 39,876 initially healthy women age 45 and over, followed for 10 years.2 Overall, the trial showed a statistically nonsignificant 9% reduction in the primary outcome of major cardiovascular events. In contrast to the significant reduction in MI and neutral effect on stroke observed in the Physicians' Health Study3 and other primary prevention trials in men,4 the WHS demonstrated that aspirin significantly lowered the risk of total stroke by 17% (95% confidence interval, 1% to 31%) and the risk of ischemic stroke by 24% (7% to 37%) in women, but did not lower the risk of MI or cardiovascular death. As expected, aspirin increased bleeding risks. Gastrointestinal hemorrhages requiring transfusion were 40% more common with aspirin, and there was also a nonsignificant 24% increase in hemorrhagic stroke risk.

However, age appeared to be a key determinant of a woman's cardiovascular response to aspirin and her benefit/risk ratio with treatment.2 Among WHS participants over age 65, aspirin was associated with clear evidence of benefit: a statistically significant 26% (8%-41%) reduction in risk of major cardiovascular events, with a significant benefit on both ischemic stroke (relative risk [RR], 0.70) and MI (RR, 0.66). In contrast, for younger participants, aspirin appeared to provide little or no cardiovascular protection (RR of major CVD events, 1.01 in women ages 45-54; 0.98 in women ages 55-64) and MI risk was not reduced in either group (RR, 1.23 and 1.17, respectively). Testing for statistical interaction by age group revealed P values for interaction of 0.05 for major CVD events and 0.03 for MI. In a benefit/risk assessment by age group, the 4,097 women who were over age 65 at enrollment experienced 44 fewer major CVD events with aspirin than with placebo (P = 0.008) but had 16 more gastrointestinal hemorrhages requiring transfusion (P = 0.05). In contrast, women under age 65 had no reduction in major CVD events, while experiencing a similar increase in gastrointestinal bleeding (leading to a net adverse effect and an unfavorable benefit/risk ratio). A woman's age appeared to be a stronger predictor of her benefit/risk ratio with aspirin than her Framingham risk score, but few women in the cohort had high 10-year coronary risks.

The perils of ageism

Ageism is still rampant in America, and many old people themselves trade in unflattering stereotypes of the elderly, including helplessness and incompetence. Such caricatures are not only false and cruel, they are also unhealthy. Research has shown that old people who believe in negative age stereotypes tend to fulfill them.

13 mar 2009--And it may not just be the elderly who are harmed by ageism. A new study in Psychological Science, a journal of the Association for Psychological Science, suggests that young, healthy people who stereotype old people may themselves be at risk of heart disease many years down the road. Researchers Becca Levy and Martin D. Slade of the Yale School of Public Health, along with Alan B. Zonderman and Luigi Ferrucci from the National Institute on Aging Intramural Research Program, examined data on hundreds of men and women who have been studied for almost four decades as part of the Baltimore Longitudinal Study of Aging. Back in 1968, when scientists began studying these volunteers, they ranged in age from 18 to 49 and were all in good health. At that time, scientists gathered all sorts of information about the volunteers, including their attitudes toward the elderly. Their images of being old covered the gamut from very positive to very negative.

The researchers examined the health histories of all the volunteers, focusing on cardiovascular disease, and they discovered that there was a striking link between ageism early in life and poor heart health later on. That is, those who viewed old age in negative terms were much more likely to experience some kind of cardiovascular disorder over the next four decades. The scientists also looked at a subset of volunteers who didn't have any heart problems until after they were 60 - at least 21 years later - and found that these people were likely to have been negative about aging from early on. The episodes of heart disease could not be explained by smoking, depression, cholesterol, family history, or any of a myriad other possible risk factors.

What this suggests, the authors write, is that people are internalizing stereotypes of old age when they are still quite young - with far reaching consequences. This is the first scientific look at people maturing into the very people they have been unkindly caricaturing. It could be taken as a cautionary tale for those who think they'll never grow old.

###

For more information about this study, please contact: Becca Levy (becca.levy@yale.edu)

Wray Herbert discusses this study in his blog, "We're Only Human..."

3 Case Western Reserve faculty ranked amongst the world's top Alzheimer's disease investigators

March issue of the Journal of Alzheimer's Disease ranks the top 100 international researchers: professor of pathology ranks 3rd in the world

13 mar 2009--Three Case Western Reserve University School of Medicine researchers were listed in the Top 100 Alzheimer's disease investigators according to a study conducted by Collexis Holdings Inc. published in the Journal of Alzheimer's Disease. The Top 100 list was released in the journal's March edition (Volume 16, Issue 3).

The researchers, Mark A. Smith, Ph.D., professor of pathology, ranked #3 in the world, Xiongwei Zhu, Ph.D. assistant professor of pathology, ranked #48, and Peter Whitehouse, M.D., Ph.D., professor of neurology, ranked #69, represent the pinnacle of a rich vein of excellence in Alzheimer's disease research and clinical expertise at the university. Case Western Reserve School of Medicine was the only academic institution in the state of Ohio to be ranked in this historic study.

Working at Case Western Reserve University since 1992, Dr. Smith currently serves as the director of Basic Science Research of the University Memory and Cognition Center and is also the executive director of the American Aging Association. "I am deeply passionate about my research and that of my colleagues here at Case Western Reserve," said Dr. Smith. "This acknowledgement speaks to the impressive and dynamic group of researchers we have at our institution and our collective dedication to finding 'A Cure From Cleveland.'" Dr. Smith added that he and others are working with pharmaceutical companies throughout the world, to translate the School of Medicine's discoveries into something tangible for patients and caregivers.

"I am delighted three School of Medicine Alzheimer's disease researchers are recognized in this landmark study of the field's Top 100 investigators," said Pamela B. Davis, M.D., Ph.D., dean of the School of Medicine and vice president, Medical Affairs for Case Western Reserve University. "We take great pride in our legacy of world-class Alzheimer's translational research and look forward to continuing our leading role."

The Journal of Alzheimer's Disease, published by Netherlands-based IOS Press, is an international multidisciplinary journal, which helps researchers understand the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews and letters to the editor and is recognized as the leading journal in the field.

According to the IOS Press, the field of Alzheimer's disease research, which celebrated its centennial in 2006, has progressed rapidly since the 1970s. Of the 135,000 actively publishing neuroscience researchers across the world, approximately 18 percent have one or more Alzheimer's disease papers to their credit.

Aaron A. Sorensen of Life Sciences Solutions Leader, Switzerland-based Collexis Holdings Inc. conducted the milestone analysis, which focused on three areas of measurement: total citations, total publications and H-index. The H-index, a statistic named after physicist Jorge Hirsch that is used more widely in Europe than in the United States, is a quantifiable measurement of a scientist's or group's productivity and the impact of that research. The Collexis study is the first objective analysis of Alzheimer's disease research through scientometrics, a field of study that measures scientific impact using a variety of measurement tools.

###

About Case Western Reserve University School of Medicine

Founded in 1843, Case Western Reserve University School of Medicine is the largest medical research institution in Ohio and 15th largest among the nation's medical schools for research funding from the National Institutes of Health. Eleven Nobel Laureates have been affiliated with the school.

Some Elderly Heart Failure Patients Get Little Help From Meds, Study Finds

As the population in the United States ages, more elderly people are being treated for heart failure. But even though they make up the majority of those treated for the disease, little is known about the effectiveness of treatment, researchers say.

"We really don't have many data on heart failure patients above the age of 80," said lead researcher Dr. Ernst R. Schwarz, medical director of the Cardiac Support Program and co-director of the Heart Transplant Program at the Cedars-Sinai Heart Institute.

In their study, the researchers looked at elderly people with diastolic dysfunction. In this condition, the systolic function of the heart is normal. "That means their pump function is normal, but their relaxation is impaired," Schwarz explained.

Diastolic dysfunction is common, affecting 50 percent of all heart failure patients, Schwarz said. It is highly prevalent among the elderly and among women, but often it is not diagnosed and not effectively treated, he said.

"We really don't know how to treat these patients because the guidelines from the American Heart Association and the American College of Cardiology are based on systolic heart failure," Schwarz said. "We do not have dedicated guidelines on the treatment of diastolic heart failure."

The report is published in the March 15 issue of the American Journal of Cardiology.

For the study, Schwarz's team studied 142 people with heart failure, who averaged 87 years old. During five years of follow-up, 69 percent of them died.

The researchers found that none of the usually prescribed drugs -- including statins, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, beta blockers, diuretics, calcium channel blockers, nitrates and digoxin -- seemed to make any significant difference in who survived and who died.

"At least for patients above the age of 80 with diastolic heart failure, whether they are treated or not with these kind of medications does not affect their mortality or their long-term outcome," Schwarz said.

Dr. Byron Lee, a cardiologist and assistant professor of medicine at the University of California, San Francisco, appeared skeptical of the findings.

"I would be very cautious when drawing conclusions from this study," Lee said. "This is not a randomized, controlled study. The patients on the cardiovascular drugs might have been much sicker than the comparison group. Therefore, the drugs may have actually had a big impact -- keeping the sicker patients alive as long as the ones not on heart medications."

Schwarz, however, speculated that lower doses of the drugs might be appropriate for people with diastolic heart failure. In any case, he said, more research is needed, as are better treatment guidelines.

"We really don't have a clue how to treat them and how to treat them better," Schwarz said. "We are at the beginning of a learning curve to try to understand the changes in the elderly organism, which might require more caution with certain drugs, more dose adjustments. We need too look at the very elderly patient in a different way."

Dr. Gregg C. Fonarow, a professor of cardiology at the University of California, Los Angeles, said that better treatments need to be found for people suffering from diastolic heart failure.

"Patients who have heart failure with preserved systolic function represent half of the 5 million patients with heart failure in the United States," Fonarow said. "These patients face substantial risk for morbidity and mortality."

Although a number of cardiovascular medications reduce mortality in people with heart failure and reduced systolic function, no medical therapy has yet shown, in randomized clinical trials, to reduce risk in people with diastolic heart failure, Fonarow said.

"There is a critical need for more research and clinical trials to identify therapies which will be effective in patients with heart failure and preserved systolic function," he said.

Two Parkinson's drugs similar for early treatment

However, each treatment has a different side-effect profile, which may determine which is the best drug for each patient, researchers report in the Archives of Neurology. Levodopa is more likely to cause dopaminergic events, whereas pramipexole is more likely to cause sleepiness and swelling from water retention.

Dopaminergic events can arise from imbalances of dopamine, a neurotransmitter in the brain that involves involuntary muscle control and movement, attention, learning, and the brain's pleasure and reward system.

The findings come from an extended follow-up study of 301 patients who participated in an earlier Parkinson's disease trial. As part of the study, clinicians were permitted to add levodopa or other antiparkinsonian drugs as needed for ongoing or emerging disability.

At 6 years' average follow-up, the scores on a scale of activities of daily living and another scale were comparable in all of the patients initially treated with levodopa versus pramipexole.

Roughly 68 percent of initial levodopa patients experienced dopaminergic motor complications compared with 50.0 percent of initial pramipexole patients. Still, disabling dyskinesias - involuntary muscle movements -- were uncommon with both treatment approaches.

The results suggest that the side effect profiles of the initial levodopa and pramipexole strategies and not their efficacy on long-term disability should guide treatment decisions, the investigators conclude.

SOURCE: Archives of Neurology, March 9, 2009.

Thursday, March 12, 2009

A simple balance test may predict cognitive decline in Alzheimer's disease

Amsterdam,12 mar 2009 – A simple balance test may predict cognitive decline in Alzheimer's Disease, according to a study published in the March 2009 issue of the Journal of Alzheimer's Disease.

This study was carried out in 16 university hospital departments of neurology, geriatrics or psychiatry in ten cities with 686 outpatients suffering from AD. This population is representative of the AD population seen by clinicians in daily practice. Patients were evaluated by a geriatrician every six months for up to two years, and their degree of cognitive impairment was measured using the Mini Mental State Examination (MMSE). At the same time, a "one-leg balance" (OLB) test was given, where a participant was asked to stand on one leg for as long as possible. The OLB test was reported as abnormal when the participant was unable to stand on one leg for 5 seconds or more.

Participants with an abnormal OLB at baseline or/and during the follow-up showed significantly more cognitive decline at 12, 18 and 24 months than the participants with a OLB test normal at baseline and normal during the follow-up. The worst condition (having an abnormal OLB at baseline and during the follow-up= no improvement) was associated with a mean adjusted cognitive decline of 9.2 points. The best condition (having a normal OLB at baseline and during the follow-up = no worsening) was associated with a mean adjusted cognitive decline of 3.8 points.

Senior Investigator Yves Rolland, Inserm and the University of Toulouse, France, states, "Our results suggested that an abnormal OLB is a marker of more advanced dementia (worst baseline characteristic) and an independent predictor of cognitive decline in AD. Our results reinforce in an AD population, the growing evidence suggesting a link between physical performances and cognitive decline. If these results are confirmed by other data, the OLB test could be adopted in clinical practice to identify AD patients at high risk of rapid cognitive decline."

###

The article is "An Abnormal 'One-leg Balance' Test Predicts Cognitive Decline During Alzheimer's Disease" by Yves Rolland, Gabor Abellan van Kan, Fati Nourhashemi, Sandrine Andrieu, Christelle Cantet, Sophie Guyonnet-Gillette and Bruno Vellas It is published in the Journal of Alzheimer's Disease 16:3 (March 2009).

'Seeing' stem cells helps in fight against peripheral arterial disease

Unique interventional radiology research puts puzzle pieces together in regenerating blood vessels to open clogged arteries, uses firefly-like bioluminescence imaging agent

SAN DIEGO, Calif., 12 mar 2009—Interventional radiologists are fitting together the puzzle pieces of how to use stem cells to create new or more blood vessels to treat peripheral arterial disease (PAD) in those individuals with extensively narrowed or clogged arteries. That puzzle may be closer to being solved in light of recent successful techniques that use simple imaging to view and locate transplanted stem cells and to confirm that they remain alive in the body once injected, notes a study presented at the Society of Interventional Radiology's 34th Annual Scientific Meeting.

PAD, which affects about 10 million Americans, is a chronic disease that progressively restricts blood flow causing poor blood circulation (generally in the legs) and if left untreated can lead to serious medical complications, including heart attack, stroke, amputation and death. Many people can manage the symptoms of PAD and stop its progression through lifestyle changes. If lifestyle changes are not enough, additional medical treatment may be needed, including prescribed medicine to prevent blood clots, lower blood pressure and cholesterol and control pain.

Interventional radiologists treat severe cases of PAD with minimally invasive treatments, including angioplasty and insertion of stents. "However, some patients have extensive disease—with so many blood vessels affected—that they're difficult to treat," said Frank Wacker, M.D., interventional radiologist at Johns Hopkins School of Medicine in Baltimore, Md. That's where stem cells—and image-guided stem cell therapy—come in. "One day, stem cells may enable the targeted delivery of cellular treatments to PAD patients who may be facing amputation and death. It will be important to deliver the right amount of drug treatment to the right place, thus allowing tailored treatment for individual patients," said Wacker. "The use of C-arm CT for image-guided delivery in the angio lab enabled us to precisely target cell delivery in relationship to blood vessels without transferring to a separate CT scanner to obtain the similar information," he added. Stem cell therapy may provide interventional radiologists with a new weapon to fight PAD, a disease that affects 12 to 20 percent of Americans age 65 and older.

"To develop new stem cell treatments for PAD, we need suitable noninvasive methods to track the fate of stem cells clearly inside the body," said veterinary radiologist Dara L. Kraitchman, V.M.D., Ph.D., an associate professor at Johns Hopkins School of Medicine. Transplanting stem cells derived from bone marrow (not embryonic stem cells), accompanied by necessary immune-suppressing drugs, has had mixed results. Rejection by the body's immune system is a likely reason for transplant failure. Because X-ray agents are toxic to stem cells, tracking of stem cell therapy cannot be done by directly labeling the stem cells themselves. Hopkins researchers used a new technique that encloses stem cells in an alginate capsule or "bubble" made from seaweed that contains stem cells to create factors to recruit the building of new vessels along with an X-ray–visible contrast agent. Tested in a rabbit model for the first time, the bubble prevents the body's immune system from reaching and attacking the transplanted cells. "We needed to figure out how to protect transplanted stem cells that are vulnerable to attack by a recipient's immune system and 'see' the cells to determine if they remained alive or not," said Kraitchman. "By making sure our protective covering for stem cells stayed intact, we were able to track where we put the stem cells and confirm whether they could survive," explained Kraitchman.

"These bubbles, which can be transplanted into a leg, can then be placed accurately at blocked blood vessels that need intervention," said Kraitchman. However, even visible with X-ray imaging, researchers could not determine if the stem cells within the bubble remained alive. Researchers then induced the stem cells within the bubble to produce luciferase, a bioluminescence imaging agent produced by fireflies—to "see" living stem cells. "We could 'see' the bubble via X-ray and tell if the stem cells remained alive as they lit up much like a firefly at night," said Kraitchman, who added that all agents used to form the bubble are approved by the Food and Drug Administration.

The future hope is to use adult stem cells extracted from a healthy donor's bone marrow and inject the cells into the patients' legs where circulation problems exist, stimulating the growth of new or more blood vessels in the leg, thus improving circulation, said Wacker. Previous studies in animals and other laboratory tests show that the injections of stem cells have such an effect and have prompted human trials, she added. Hopkins researchers took rabbit stem cells—separated from bone marrow in the lab—and injected them into the animal's hind quarter to track them. "Our research could eventually help PAD patients by providing a process for stem cells to thrive in the body and make more blood vessels or new blood vessels," he noted. "Using an animal model, we found that our research opens the door to delivering stems cells exactly where they are needed, allowing them to 'recruit' new blood vessels," added Wacker.

Bone marrow stem cells, which have the ability to renew themselves, could unlock the door to treat PAD with cell-based treatments. Stem cells are master or undifferentiated cells that have the ability to continuously divide and develop into other specialized types of cells. When conditions are just right, stem cells can begin to develop into specialized tissues and organs or turn into more specialized cells that are self-sustaining by replicating through cell division. Once healthy stem cells are harvested like blood for blood tranfusions, they could be injected into a diseased part of the body for growing healthier new blood vessels. Because of their uniqueness, researchers are exploring the use of stem cells for the treatment of life-threatening diseases.

###

More information about peripheral arterial disease and interventional radiology can be found online at www.SIRweb.org.

Abstract 133: "Using X-ray Trackable Encapsulated Stem Cells to Guide Reporter Probe Delivery with C-Arm CT," D.A. Kedziorek, P. Walczak, Y. Fu, F. Wacker, D.L. Kraitchman, Johns Hopkins University, Baltimore, Md., SIR 34th Annual Scientific Meeting March 7-12, 2009. This abstract can be found at www.SIRmeeting.org.

Simple test helps predict heart attack risk

Ankle brachial index identifies peripheral arterial disease patients at high cardiovascular risk who were missed by Framingham Risk Score in 6,200-person NHANES study

SAN DIEGO, Calif.,12 mar 2009—The use of common and readily available screening tests—like the ankle brachial index (ABI)—along with traditional risk scoring systems—such as the Framingham Risk Score—has the potential to prevent devastating heart attacks in thousands of individuals who are not originally thought to be at high risk (according to Framingham alone), say researchers at the Society of Interventional Radiology's 34th Annual Scientific Meeting. About 25 percent of all heart attacks or sudden cardiac deaths in the United States occur in individuals thought to be at low risk.

In the study, information was analyzed from the 1999-2004 National Health and Nutrition Examination Survey (NHANES)—a nationally representative cross-sectional survey of the U.S. population for 6,292 men and women ages 40 and older without known history of heart disease, stroke, diabetes or atherosclerotic vascular disease—along with available data on standard cardiovascular risk factors and screening tests (like the ABI, which is a comparative blood pressure test). For the first time, researchers determined the prevalence of peripheral arterial disease (PAD) in a large population of women and men who were not considered at high risk for cardiovascular disease. And the results are surprising: novel risk factors (those not traditionally considered in the Framingham Risk Score) are abnormal in up to 45 percent of those not considered high risk for coronary heart events.

"This is significant news that can profoundly impact public health. If novel risk factors are shown to improve risk prediction, they could be very valuable because the prevalence of abnormal values is high in populations not known to have high risk," said Timothy P. Murphy, M.D., an interventional radiologist and director of the Vascular Disease Research Center at Rhode Island Hospital in Providence. "These simple tests—like ABI screening—have the potential to improve the accuracy of cardiovascular risk prediction and thereby have significant public health impact by helping identify people for intensive medical therapy and preventing heart attacks and strokes," said Murphy.

While 91 percent of the NHANES group was considered at low or intermediate risk of cardiovascular disease, according to Framingham criteria alone, almost 45 percent of them were found to have at least one of three conditions: an abnormal ABI or elevated plasma fibrinogen or elevated plasma C-reactive protein (CRP). "Even with abnormal ABI, which was the least prevalent of the three novel risk factors evaluated, that number translates into about 2.1 million Americans, age 40 and older, who have no known history of heart disease, stroke, diabetes or atherosclerotic vascular disease," said Murphy. "There is also a good chance that ABI, which actually detects subclinical already-established atherosclerotic disease, may actually perform better in terms of risk prediction than fibrinogen or C-reactive protein because it may be more specific," Murphy said.

About 1.1 million Americans every year have heart attacks, and almost a third of those heart attacks results in death. Another 750,000 individuals experience stroke each year. Risk factors—like smoking, diabetes, high blood pressure and obesity—increase one's risk of heart attack and are associated with 75 percent of all heart attacks. However, the other 25 percent of heart attacks or sudden cardiac deaths occur in individuals not known to have risk factors and thought to be at low risk for cardiovascular disease. "The earlier the detection of who's at risk for heart attacks is crucial. Primary prevention—such as initiating lifestyle changes and medical intervention directed at modifying risk factors (smoking cessation, blood glucose and blood pressure control, lowering cholesterol and exercise)—can be started to improve one's health before costlier and more intensive interventions are needed," said Murphy.

"Interventional radiologists often provide PAD screening tests like the ABI. Primary care doctors, who oversee medical management of the vast majority of the public at risk for cardiovascular disease, should partner with interventional radiologists in evaluating patients' risk for cardiovascular disease, as well as for managing established PAD," said Murphy. ABI, used to diagnose PAD, is a painless test that compares the blood pressure in the legs to the blood pressure in the arms to determine how well the blood is flowing and whether further tests are needed. Elevated results for plasma fibrinogen and plasma C-reactive protein, laboratory-based tests, can indicate inflammation.

###

More information about ABI, cardiovascular disease, and interventional radiology can be found online at www.SIRweb.org.

Abstract 146: "Prevalence of Low Ankle Brachial Index, Elevated Plasma Fibrinogen and CRP Among Those Otherwise at Low-Intermediate Cardiovascular Events' Risk: Data From the National Health and Nutrition Examination Survey (NHANES) 1999჻�," R. Dhangana, T.P. Murphy, M.B. Ristuccia, J.V. Cerezo and D. Tsai, all with Rhode Island Hospital/Brown University, Providence, R.I.; and M.J. Pencina, Boston University, Boston, Mass., SIR 34th Annual Scientific Meeting March 7-12, 2009. This abstract can be found at www.SIRmeeting.org.

Study suggests blood test for Alzheimer's possible

Athens, Ga., 12 mar 2009 – Researchers have revealed a direct relationship between two specific antibodies and the severity of Alzheimer's disease symptoms, raising hopes that a diagnostic blood test for the devastating disorder is within reach.

Researchers from the University of Georgia, the Charlie Norwood VA Medical Center in Augusta and the Medical College of Georgia compared antibody levels in blood samples from 118 older adults with the participant's level of dementia. The team, whose results appear in the current edition of Journal of Gerontology: Medical Sciences, found that the concentration of two specific proteins that are involved in the immune response increases as the severity of dementia increases.

"We found a strong and consistent relationship between two particular antibodies and the level of impairment," said study co-author L. Stephen Miller, professor and director of clinical psychology training in the UGA Franklin College of Arts and Sciences. "The finding brings us closer to our ultimate goal of developing a blood test that can diagnose Alzheimer's disease or potentially identify if someone is at higher risk for the disease."

Miller's co-authors include Jennifer S. Wilson, a former undergraduate student in the UGA Honors program who is now pursing graduate studies at Emory University; Shyamala Mruthinti, research pharmacologist at the VA Medical Center and adjunct professor at MCG; and Jerry Buccafusco, director of the MCG Alzheimer's Research Center. The team focused on antibodies that the body creates in response to two proteins that are associated with Alzheimer's disease. One protein, known as amyloid-beta, forms the plaques that are evident in the brains of people with Alzheimer's upon autopsy. The other protein, known as RAGE, is involved in the normal aging process but is expressed at higher levels in the brains of people with Alzheimer's.

In a previous study that compared a group of people with Alzheimer's disease to a healthy control group, Mruthinti and her colleagues found that anti-amyloid beta and anti-RAGE antibodies are significantly higher in the group with Alzheimer's. The team's latest study expands on that finding to reveal a direct relationship between severity of Alzheimer's disease and levels of the two antibodies in the blood.

"Alzheimer's is an inflammatory disease of the brain, and these two antibodies give us a way to measure that inflammation," Mruthinti said. "Using them as an early diagnostic marker may allow us to start drug treatment early, when it's most effective, to increase the patient's quality of life."

While optimistic about their findings, the researchers caution that it could still be years before a diagnostic test based on their work is clinically available. The study found that the relationship between the two antibodies and Alzheimer's severity persists even after controlling for patient age and total antibody levels. To further test the strength of the relationship, the researchers are now working with a sample that controls for other factors that have the potential to influence levels of the two antibodies, such as diabetes and heart disease. Buccafusco and his colleagues are also working to decrease the cost and time involved in the test.

"We're in the process of trying to reduce the test to a one-day procedure, whereas right now it takes three to four days," Buccafusco said. "But even now, our test is orders of magnitude cheaper than having people come in every few months to get a functional MRI or PET scan to try to discern brain plaques."

The team is targeting the two proteins themselves as a possible treatment for Alzheimer's disease. Mruthinti explains that, individually, amyloid-beta and RAGE proteins don't provoke an immune response. The trouble begins when the two bind and the immune system attacks, resulting in constant state of inflammation that damages the brain. The researchers recently developed a way to measure levels of amyloid beta-RAGE complex, and preliminary data using transgenic mice that express Alzheimer's symptoms suggest that an antigen they created to boost the body's natural immune response to the complex can reduce the formation of the brain plaques.

"The amyloid beta-RAGE complex cuts off the connections between neurons," Mruthinti explained, "but our hope is that we can protect those connections by preventing those plaques from forming."

Telehealth for diabetes promotes aging at home, not in the hospital

INDIANAPOLIS,12 mar 2009– A large study of ethnically and racially diverse individuals with diabetes has found that home telemonitoring of their health resulted in significantly fewer deaths than in a similar group that was not monitored. Diabetes is the sixth leading cause of death in the United States.

The study of 387 diabetics and 387 individuals without diabetes appears in the March 2009 issue of the Journal of Telemedicine and Telecare.

The researchers, led by Neale Chumbler, Ph.D., professor of sociology at Indiana University-Purdue University Indianapolis's School of Liberal Arts and a Regenstrief Institute research scientist, used home telemonitoring technology to support timely transmission of diabetics' symptoms and health status at least once a day to a nurse coordinator who managed the process and acted upon the information when necessary or when requested by the patient.

"People want the freedom to remain in their homes. Telehealth appears to provide a safety net that will allow some of them – such as the growing number of individuals with diabetes – to age in place and to live where they want to live," said Dr. Chumbler, a medical sociologist who studies access to care and is associate chief of the Center of Excellence on Implementing Evidence-based Practice at the Roudebush VA Medical Center in Indianapolis.

Unless diabetes symptoms are closely monitored, the risk of death from the disease increases significantly. Approximately 25 percent of VA patients have diabetes.

The telemonitoring study, which followed VA patients with diabetes for four years, also provided educational resources to trial participants. "This study demonstrates the effectiveness of chronic care management for diabetes and the feasibility of using telehealth to carry it out," said Dr. Chumbler.

The magnitude and significance of home telehealth effects on mortality for those with diabetes had not previously been demonstrated. This new study contributes to the growing list of scientific evidence regarding the effectiveness of care monitoring for a variety of chronic conditions. "Telemonitoring may be one of the most effective and cost effective ways of helping individuals avoid constant visits to their doctor's office or hospitalization."

###

Authors of "Mortality Risk for Diabetes Patients in a Care Coordination/Home-Telehealth Program" in addition to Dr. Chumbler are David Haggstrom, M.D. of the Indiana University School of Medicine, the Regenstrief Institute, and Center of Excellence on Implementing Evidence-based Practice at the Roudebush VAMC, researchers from the VA Medical Center in Gainesville, Fla. and the University of Florida. The study was funded by U.S. Department of Veterans Affairs.

Wednesday, March 11, 2009

Obesity, Diabetes and Heart Disease May Speed Dementia

One expert thinks these papers, published in the March issue of Neurology, deliver a key message, namely that people can take steps to reduce their risk of developing dementia and Alzheimer's disease. People think about lifestyle factors in preventing heart disease, he says, but not always when it comes to losing mental abilities.

"This is an important message," said Dr. Ronald C. Petersen, chairman of the Medical and Scientific Advisory Council of the Alzheimer's Association and director of the Alzheimer's Disease Research Center at the Mayo Clinic. "Development of cognitive decline need not be a passive process."

"We are not all just sitting here and aging, and sooner or later it's going to hit us," said Petersen, who was not involved in the studies. "In fact, there may be some modifiable lifestyle factors that may influence our risk of developing cognitive impairment and Alzheimer's disease down the road."

In one report, Dr. Kristine Yaffe, a professor at the University of California, San Francisco, and director of the Memory Disorders Clinic at the San Francisco Veterans Affairs Medical Center, found that among older women, obesity, high blood pressure and a low level of HDL, the "good" cholesterol -- collectively labeled metabolic syndrome -- were each associated with a 23 percent increase in risk for cognitive impairment.

Yaffe's research team collected data on 4,895 women who averaged 66 years old and who had no cognitive impairment at the start of the study. Among the 497 women with metabolic syndrome, about 7 percent developed cognitive impairment, compared with 4 percent of the women without the condition.

"As the obesity and sedentary lifestyle epidemic escalates throughout the world, identification of the role of these modifiable behaviors in increasing risk for development of deleterious outcomes, such as cognitive impairment, is critical," the authors concluded.

In a second study, Yaffe's group found a cognitive risk for obese men, too. For that study, the researchers collected data on 3,054 older men and women.

Comparing people's scores on tests given at the beginning of the study and again three, five and eight years later, the researchers discovered that obese men were more likely to show signs of cognitive decline. However, there was no correlation between obesity and cognitive decline among women, the study reported.

A third report found a different trend. In that study, Annette L. Fitzpatrick, a research associate professor of epidemiology at the University of Washington, in Seattle, and colleagues found that obesity in middle age increased the risk for dementia. However, after age 65, underweight people rather than obese people were at higher risk for dementia.

In fact, obesity appeared to have a protective effect, the researchers noted.

They had collected data on 2,798 men and women who averaged 75 years old and who did not have dementia at the start of the study. During more than five years of follow-up, 480 people developed dementia; in 245 people, it was determined to be Alzheimer's disease.

"The greatest dementia risk was found in underweight individuals at older ages," the researchers concluded. "These findings suggest the predictive ability of BMI [body-mass index] changes across time." They added that the findings "help explain the 'obesity paradox' as differences in dementia risk across time are consistent with physical changes in the trajectory toward disability."

In the fourth report, Elizabeth P. Helzner and colleagues from Columbia University Medical Center in New York City collected data on 156 people diagnosed with Alzheimer's disease at an average age of 83.

They found that people with higher total and LDL, or "bad," cholesterol levels and diabetes had a more rapid cognitive decline after developing Alzheimer's disease.

The study "provides further evidence for the role of vascular risk factors in the course of Alzheimer's disease," the researchers concluded. "Prevention or treatment of these conditions can potentially slow the course of Alzheimer's disease."

More and more data are showing the connection between lifestyle and cognitive decline, Petersen stressed. "This series of articles underlines that," he said.

And people need to improve these lifestyle factors in middle age, he said.

"People should start paying attention now, regardless of your age or stage in life," he said. "It may be when you are in midlife, when you are in your 40s or 50s, what you do then with respect to your lifestyle -- your diet, your weight, your activity level -- may have a bigger impact on what's going to happen to you at age 70 and beyond than if you wait until you start getting a little forgetful or a little bit fuzzy."

Parkinson's Treatment Drugs Even Out Over Long Term

That's the conclusion of a new study that included hundreds of patients in Canada and the United States.

"Clinicians and patients often struggle with what is the right initial approach to treating Parkinson's disease. This study tells us that, over the long haul, patients on the different drugs end up at roughly the same place in terms of their level of disability and quality of life," lead author Dr. Kevin Biglan, a neurologist at the University of Rochester Medical Center in New York, said in a school news release.

The two drugs use different mechanisms to counteract the decline in the production of dopamine in the brain that causes Parkinson's symptoms. Levodopa is an amino acid that the body metabolizes into dopamine. Pramipexole binds with dopamine receptors on cells in the brain and mimics dopamine's molecular function.

Levodopa is considered better at treating motor control problems in Parkinson's patients but is also associated with side effects such as dyskinesia (involuntary movements), and the effectiveness of the drug can wear off over time. Pramipexole is less commonly associated with dyskinesea and wearing off, but is less effective in treating motor control problems and more often causes sleepiness, according to background information in the news release.

Doctors often prescribe pramipexole first, because it extends the length of time a patient can benefit from levodopa before its effect wears off.

The initial study included 301 patients at 22 sites who were followed for two years. A subset of 222 of those patients was followed for an additional four years. At the start of the study, half the patients were randomly selected to receive levodopa and half to receive pramipexole. After six years of follow-up, 90 percent of patients were taking levodopa.

Patients initially treated with levodopa were more likely to develop motor control complications such as dyskinesia and wearing off, but these complications didn't have a significant impact on patients' quality of life or disability, the researchers found.

The study, published online March 9 in the journal Archives of Neurology, was funded by Pharmacia Corp. and Boehringer Ingelheim.

Red wine vs. white? It makes no difference when it comes to breast-cancer risk

SEATTLE, 11 mar 2009 – The largest study of its kind to evaluate the effect of red versus white wine on breast-cancer risk concludes that both are equal offenders when it comes to increasing breast-cancer risk. The results of the study, led by researchers at Fred Hutchinson Cancer Research Center, were published in the March issue of Cancer Epidemiology, Biomarkers and Prevention.

"We were interested in teasing out red wine's effects on breast-cancer risk. There is reason to suspect that red wine might have beneficial effects based on previous studies of heart disease and prostate cancer," said lead author Polly Newcomb, Ph.D., M.P.H., head of the Cancer Prevention Program in the Public Health Sciences Division at the Hutchinson Center. "The general evidence is that alcohol consumption overall increases breast-cancer risk, but the other studies made us wonder whether red wine might in fact have some positive value."

Instead, Newcomb and colleagues found no compelling reason to choose Chianti over Chardonnay.

"We found no difference between red or white wine in relation to breast-cancer risk. Neither appears to have any benefits," Newcomb said. "If a woman drinks, she should do so in moderation – no more than one drink a day. And if a woman chooses red wine, she should do so because she likes the taste, not because she thinks it may reduce her risk of breast cancer," she said.

The researchers found that women who consumed 14 or more drinks per week, regardless of the type (wine, liquor or beer), faced a 24 percent increase in breast cancer compared with non-drinkers.

For the study, the researchers interviewed 6,327 women with breast cancer and 7,558 age-matched controls about their frequency of alcohol consumption (red wine, white wine, liquor and beer) and other breast-cancer risk factors, such as age at first pregnancy, family history of breast cancer and postmenopausal hormone use. The study participants, ages 20 to 69, were from Wisconsin, Massachusetts and New Hampshire. The frequency of alcohol consumption was similar in both groups, and equal proportions of women in both groups reported consuming red and white wine.

###

The National Cancer Institute, a branch of the National Institutes of Health, funded this research, which also involved investigators from Group Health Cooperative, Seattle; the University of Wisconsin; H. Lee Moffitt Cancer Center & Research Institute; and Dartmouth Medical School.

Mutation of BRCA gene influences women's views of preventive mastectomy

11 mar 2009--Women whose cells harbor harmful mutations in the BRCA genes are likely to view preventive mastectomy as the best way to reduce their risk and fears of developing breast cancer, despite other, less drastic options available. That is the conclusion of a new study published in the April 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The study's findings could help physicians and other clinicians as they discuss test results with women who undergo BRCA gene testing.

Women at high risk for developing breast cancer have several options to help safeguard against the disease. Risk management for women with a known deleterious mutation in either the BRCA1 or BRCA2 genes has included frequent screening with mammogram, breast MRI, and clinical breast exams, tamoxifen therapy, and risk reduction surgeries including prophylactic mastectomy. To get a sense of women's opinions regarding those options, particularly frequent screening versus prophylactic mastectomy, researchers led by Jennifer K. Litton, M.D., of The University of Texas M. D. Anderson Cancer Center in Houston surveyed women at their institution who underwent BRCA1 and BRCA2 genetic testing. When mutated, BRCA1 and BRCA2 are known to elevate the risk for the development of breast cancer.

Of the 312 women surveyed, 86 had tested positive for a BRCA mutation. Seventy percent of the women who tested positive for a BRCA mutation felt that preventive mastectomy was the most effective way to reduce their risk of developing breast cancer, compared with 40 percent of women who tested negative for a BRCA mutation. Similarly, 64.7 percent of BRCA positive women felt that preventive mastectomy was the only way to reduce their worry, compared with 34.4 percent of BRCA negative women.

The investigators found that about eight out of ten women (81 percent) who viewed preventive mastectomy as the best way to reduce cancer risk decided to undergo the procedure. A similar number of those who felt that preventive mastectomy was the only way to reduce worry underwent the procedure (84.2 percent).

The survey also revealed that none of the women who tested positive for a BRCA mutation and 5.4 percent of BRCA negative women felt that mammograms were difficult to get because the procedure was too uncomfortable.

The researchers concluded that women's opinions regarding preventive mastectomy and their ultimate choice to undergo the procedure were highly dependent upon their BRCA genetic testing results. "Health care providers and genetic counselors must take this into account when assessing a woman's needs at the time of genetic testing and results disclosure," the authors wrote.

###

Article: "Perception of screening and risk-reduction surgeries in patients tested for a BRCA deleterious mutation." J.K. Litton, S.N. Westin, K. Ready, C.C. Sun, S.K. Peterson, F. Meric-Bernstam, A.M. Gonzalez-Angulo, D.C. Bodurka, K.H. Lu, G.N. Hortobagyi, and B.K. Arun. CANCER; Published Online: March 9, 2009 (DOI: 10.1002/cncr.24119); Print Issue Date: April 15, 2009.

Depression leads to higher health care costs for women cardiovascular patients, national study shows

WHAT: Women with suspected coronary artery disease who suffer from depression have significantly higher health care costs than those who are not depressed, according to findings from the Women's Ischemia Syndrome Evaluation (WISE), an ongoing, multicenter study funded by the National Institutes of Health.

11 mar 2009--Previous studies have shown that patients suffering from certain medical conditions and depression have greater health expenses than those without depression. Because women are diagnosed with depression at twice the rate of men, the study of costs related to depression and women's health issues is particularly important.

WHO: C. Noel Bairey Merz, M.D., is available to provide additional details. She is one of the journal article authors and chair of the multicenter WISE initiative, which is investigating potential methods for more effective diagnosis and evaluation of coronary artery disease in women. Bairey-Merz serves as director of the Women's Heart Center at the Cedars-Sinai Heart Institute, where she also directs the Preventive and Rehabilitative Cardiac Center at the Cedars-Sinai Heart Institute. A professor of medicine at Cedars-Sinai Medical Center, she holds the Women's Guild Endowed Chair in Women's Health.

DETAILS: This study, conducted among 868 women undergoing evaluations for possible coronary artery disease, used three different approaches to measure depression (history of treatment for depression, use of antidepressant medications, and a standard, widely accepted questionnaire). Seventeen percent to 45 percent of the women in the study met depression criteria.

Depression was associated with 15 percent to 53 percent increases in cardiovascular costs over five years. Translated into dollar figures, annual cardiovascular costs were $1,550 to $3,300 higher for depressed women than for those who were not depressed (depending on the depression criteria used).

Several factors appear to be responsible for these increased costs, but one clear association is the fact that the depressed women experienced more cardiovascular disease events. Interestingly, relationships between depression and costs were particularly strong among women who did not have evidence of significant coronary artery disease, suggesting that depression may play a larger cost role in women who do not have traditional markers of heart disease. These results combined with prior work suggest that women with symptoms of heart disease without obstructive CAD are more prone to depression possibly secondary to misdiagnosis and misunderstanding. More research is needed," said Bairey Merz.

RAMIFICATIONS: The findings suggest that depression is an important factor in understanding overall and cardiovascular-related costs in women who have symptoms of heart disease. Although it is not currently known whether treatment for depression can lower costs in cardiac populations, the results support future research in this area.

FUNDING: The study was funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health, the National Center for Research Resources, the Gustavus and Louis Pfeiffer Research Foundation, The Women's Guild of Cedars-Sinai Medical Center, The Ladies Hospital Aid Society of Western Pennsylvania, and the Edythe Broad Endowment for Women's Heart Research.

###

The study abstract can be accessed at http://content.onlinejacc.org/cgi/content/abstract/53/2/176

Tuesday, March 10, 2009

Hatha yoga practice and fear of falling in older adults

IU researchers find promising results

10 mar 2009--Indiana University researchers found promising results in an exploratory study involving yoga practice by older adults who expressed a fear of falling. After a 12-week, twice weekly hatha yoga class, taught by a professional yoga therapist, study participants reported a reduced fear of falling, increased lower body flexibility and a reduction in their leisure constraints.

Fear of falling is an important public health concern because it can cause older adults -- even those who have not fallen -- to limit their social and physical activity. This effort to avoid falls can create a harmful cycle that can diminish health and quality of life.

"Our study found that yoga was a feasible intervention with older adults and that they perceived great benefit from it," said Marieke Van Puymbroeck, assistant professor in the Department of Recreation, Park and Tourism Studies in IU's School of Health, Physical Education and Recreation.

Van Puymbroeck discussed some of her findings this month at the International Association of Yoga Therapists' Symposium for Yoga Therapy and Research in Los Angeles and will discuss her findings further at conferences hosted by the American Geriatrics Society and the American Therapeutic Recreation Association. More about the study:

  • The study involved 14 men and women with an average age of 78. Five participants had fallen previously.
  • Van Puymbroeck said the 90 percent weekly attendance rate was notable, as was the 6 percent dropout rate, which she said was much lower than most physical activity and yoga studies. The participants took a class in hatha yoga, which is a gentle form of yoga that easily can be adapted for individual needs and can be performed from a seated position. The twice weekly classes each lasted 60 minutes.
  • After the 12-week class, participants reported a 6 percent reduction in their fear of falling, a 34 percent increase in lower body flexibility, and a statistically significant reduction in leisure constraints.
  • Van Puymbroeck said participants reported "tremendous benefits," with emerging themes that included the ability to generalize principals of posture to other situations, increased range of motion, increased flexibility and improved balance.
###

Co-investigators include David Koceja, Department of Kinesiology in IU Bloomington's School of HPER; and Arlene Schmid, Department of Occupational Therapy and Department of Veterans Affairs, Indiana University-Purdue University Indianapolis.

Vascular Risks May Speed Cognitive Decline in Alzheimer's

Pre-diagnosis cholesterol abnormalities or diabetes may accelerate cognitive decline

10 mar 2009-- Pre-existing vascular risk factors such as abnormal cholesterol levels and diabetes may be associated with an accelerated cognitive decline in patients diagnosed with Alzheimer's disease, according to the results of a study published in the March issue of the Archives of Neurology.

Elizabeth P. Helzner, Ph.D., of Columbia University in New York City, and colleagues studied 156 patients who were diagnosed with Alzheimer's disease at a mean age of 83 and followed them for a mean of 3.5 years.

The researchers found that subjects with higher pre-diagnosis levels of low-density lipoprotein cholesterol and total cholesterol experienced a more rapid decline on cognitive test scores than those whose cholesterol levels were in the normal range. They also found that subjects with a history of diabetes had a more rapid decline in test scores compared to non-diabetics. Among subjects with a history of heart disease and stroke, declines were only observed in carriers of the apolipoprotein E e4 gene.

The study "provides further evidence for the role of vascular risk factors in the course of Alzheimer's disease," the authors conclude. "Prevention or treatment of these conditions can potentially slow the course of Alzheimer's disease."

Abstract
Full Text (subscription or payment may be required)

Depression Symptoms in Stable COPD Linked to Mortality

Stable COPD patients with depressive symptoms have nearly doubled mortality risk

10 mar 2009-- Depression symptoms occurring in patients with stable chronic obstructive pulmonary disease (COPD) are associated with all-cause mortality, according to a report published in the March issue of Chest.

Jacob N. de Voogd, of the University Medical Center Groningen in the Netherlands, and colleagues evaluated the presence of depressive symptoms in 121 patients with stable COPD with a mean age of 61.5 years. Depressive symptoms were assessed with a self-administered survey, and patients were followed for 8.5 years.

The mortality rate over the study follow-up period was 63 percent, and the median survival time was 5.3 years, the researchers report. Depressive symptoms were significantly associated with all-cause mortality (odds ratio, 1.93). This association occurred independently of the evaluated patient characteristics, including gender, age and peak workload level, the report indicates.

"This study provides evidence that depressive symptoms assessed in stable patients with COPD are associated with their subsequent all-cause mortality," the authors conclude. Although this link was previously reported, "this is one of the first studies demonstrating that there is an association even in stable COPD patients."

Abstract
Full Text (subscription or payment may be required)